Intercure (INCR) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rallybio (RLYB) has outperformed Intercure (INCR) over the past year, gaining 208.4% versus a loss of 50.6%. Over five years, RLYB leads with a -85.3% price change compared with -90.9% for INCR. Rallybio is the larger company by market cap ($43.3 million vs $42.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCR | RLYB |
|---|---|---|
| Share price | $3.24 | $15.47 |
| Market cap | $42.03M | $43.32M |
| 1-day change | -7.69% | -0.32% |
| YTD return | -28.79% | +181.89% |
| 1-year return | -50.57% | +208.41% |
| 5-year return | -90.87% | -85.29% |
| P/E ratio (TTM) | — | 3.36 |
| EPS (TTM) | $-0.95 | $4.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $858.00K |
| Revenue growth (YoY) | — | +34.91% |
| Net income (latest FY) | — | $-8.98M |
| Operating margin | — | -3853.61% |
| Net margin | — | -1046.39% |
| 52-week high | $7.55 | $35.15 |
| 52-week low | $3.12 | $7.34 |
| Distance from 52-week high | -57.09% | -55.99% |
| Average volume | 15.93K | 10.14K |
| Shares outstanding | 12.97M | 2.80M |
| Employees | 285 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed INCR by 259.0 percentage points over the past year.
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
INCR vs RLYB FAQ
Which is bigger, Intercure or Rallybio?
Rallybio (RLYB) is larger, with a market capitalization of $43.32M compared with $42.03M for Intercure (INCR).
Which stock has performed better over the past year, INCR or RLYB?
RLYB returned +208.41% over the past 12 months, compared with -50.57% for INCR (price return, excluding dividends). Past performance does not predict future results.
Are Intercure and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.